Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HS-10352
i
Other names:
HS-10352, HS10352, HS 10352
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Jiangsu Hansoh Pharma
Drug class:
PIK3CA inhibitor
Related drugs:
‹
alpelisib (80)
copanlisib (32)
GDC-0032 (22)
CYH33 (8)
inavolisib (4)
LX-086 (3)
AZD8835 (1)
BPI-21668 (0)
SL-901 (0)
TOS-358 (0)
TQ-B3525 (0)
MLN1117 (0)
alpelisib (80)
copanlisib (32)
GDC-0032 (22)
CYH33 (8)
inavolisib (4)
LX-086 (3)
AZD8835 (1)
BPI-21668 (0)
SL-901 (0)
TOS-358 (0)
TQ-B3525 (0)
MLN1117 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
HS-10352
Sensitive: C3 – Early Trials
HS-10352
Sensitive
:
C3
HS-10352
Sensitive: C3 – Early Trials
HS-10352
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login